NO160137C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.

Info

Publication number
NO160137C
NO160137C NO813804A NO813804A NO160137C NO 160137 C NO160137 C NO 160137C NO 813804 A NO813804 A NO 813804A NO 813804 A NO813804 A NO 813804A NO 160137 C NO160137 C NO 160137C
Authority
NO
Norway
Prior art keywords
pyrimidines
diamino
substituted
preparation
therapeutic active
Prior art date
Application number
NO813804A
Other languages
English (en)
Other versions
NO160137B (no
NO813804L (no
Inventor
Susan Mary Daluge
Paul Marcel Skonezny
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO813804L publication Critical patent/NO813804L/no
Publication of NO160137B publication Critical patent/NO160137B/no
Publication of NO160137C publication Critical patent/NO160137C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO813804A 1980-11-11 1981-11-10 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner. NO160137C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8036135 1980-11-11

Publications (3)

Publication Number Publication Date
NO813804L NO813804L (no) 1982-05-12
NO160137B NO160137B (no) 1988-12-05
NO160137C true NO160137C (no) 1989-03-15

Family

ID=10517217

Family Applications (2)

Application Number Title Priority Date Filing Date
NO813804A NO160137C (no) 1980-11-11 1981-11-10 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.
NO1994029C NO1994029I1 (no) 1980-11-11 1994-12-29 Baquiloprim/ 2,4-diamino-5-(8-dimetylamino-7-metyl-5-kinolylmetyl)pyrimidin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1994029C NO1994029I1 (no) 1980-11-11 1994-12-29 Baquiloprim/ 2,4-diamino-5-(8-dimetylamino-7-metyl-5-kinolylmetyl)pyrimidin

Country Status (35)

Country Link
US (4) US4438267A (no)
EP (1) EP0051879B1 (no)
JP (1) JPS57114581A (no)
KR (1) KR880001736B1 (no)
AR (1) AR245447A1 (no)
AU (1) AU549449B2 (no)
CA (1) CA1186310A (no)
CS (1) CS273153B2 (no)
CY (1) CY1419A (no)
DD (1) DD201896A5 (no)
DE (1) DE3173752D1 (no)
DK (1) DK172884B1 (no)
EG (1) EG16107A (no)
ES (5) ES8307759A1 (no)
FI (1) FI76333C (no)
GB (1) GB2087881B (no)
GR (1) GR81317B (no)
HK (1) HK23388A (no)
HU (1) HU188762B (no)
IE (1) IE52128B1 (no)
IL (1) IL64256A (no)
IT (1) IT1210589B (no)
MC (1) MC1418A1 (no)
MY (1) MY8600678A (no)
NO (2) NO160137C (no)
NZ (1) NZ198932A (no)
PH (2) PH22654A (no)
PL (4) PL139827B1 (no)
PT (1) PT73960B (no)
RU (1) RU1819264C (no)
SG (1) SG62686G (no)
SU (4) SU1424732A3 (no)
YU (5) YU42444B (no)
ZA (1) ZA817780B (no)
ZM (1) ZM9481A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
DK190983A (da) * 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
ZA833067B (en) * 1982-05-01 1984-12-24 Wellcome Found Antibacterial compounds
US4590271A (en) * 1982-05-01 1986-05-20 Burroughs Wellcome Co. 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4587341A (en) * 1982-05-07 1986-05-06 Burroughs Wellcome Co. 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials
CA1244028A (en) * 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
GB8603964D0 (en) * 1986-02-18 1986-03-26 Cooper Animal Health Ltd Compositions
GB8603962D0 (en) * 1986-02-18 1986-03-26 Wellcome Found Chemical compositions
LU86703A1 (fr) * 1986-12-08 1988-07-14 Oreal Composition cosmetique photostable contenant un filtre uv-a et un filtre uv-b,son utilisation pour la protection de la peau contre les rayons uv et procede de stabilisation du filtre uv-a par le filtre uv-b
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
GB8903978D0 (en) * 1989-02-22 1989-04-05 Coopers Animal Health Chemical compositions
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
RU95113597A (ru) * 1992-12-02 1997-06-10 ФМК Корпорейшн (US) Инсектицидная композиция, способы борьбы с насекомыми
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
EP0866791B1 (en) * 1995-12-04 2002-01-30 Arpida AG, Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial
WO2002010156A1 (en) * 2000-07-29 2002-02-07 Arpida Ag Benzofuran derivatives and their use as antibacterial agents
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
EP1401413B1 (en) * 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
EP1461032B1 (en) * 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
DE60228278D1 (de) * 2001-09-20 2008-09-25 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
CA2461181A1 (en) * 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
DE602004027384D1 (de) * 2003-07-11 2010-07-08 Arpida Ag Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen
CZ2007537A3 (cs) * 2005-02-18 2008-02-20 Arpida Ag Nové zpusoby výroby benzofuranové slouceniny
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2778931A1 (en) * 2009-06-12 2010-12-16 Marianne Allard Guanine riboswitch binding compounds and their use as antibiotics
CN102649786B (zh) * 2011-02-28 2014-08-27 郑州福源动物药业有限公司 一种2,4-二氨基-5-(8-二甲氨基-7-甲基-5-喹啉基甲基)-2,4-(1h,3h)嘧啶的制备方法
CN103755684B (zh) * 2014-02-10 2015-09-09 青岛蔚蓝生物股份有限公司 一种巴喹普林的制备方法
CN113924293B (zh) * 2019-06-06 2024-07-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
US20240226100A1 (en) * 2021-04-09 2024-07-11 The Trustees Of The University Of Pennsylvania Control of protein expression with tmp-protac compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3049544A (en) * 1962-08-14 Method for the preparation of
DE1303727B (de) 1959-09-03 1976-02-05 Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London Alpha-Arylidensubstituierte Propioni-Irile
US3956327A (en) * 1969-03-06 1976-05-11 Burroughs Wellcome Co. Method of preparing 2,4-diamino-5-benzyl pyrimidines
BE792096A (fr) * 1971-12-01 1973-05-30 Hoffmann La Roche Nouvelles benzylpyrimidines
GB1468374A (en) 1974-03-06 1977-03-23 Wellcome Found Process for preparing a pyrimidine derivative
US4039543A (en) 1974-12-24 1977-08-02 Hoffmann-La Roche Inc. Benzylpyrimidines
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
DE2730467A1 (de) * 1977-07-06 1979-01-18 Basf Ag Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4258045A (en) * 1979-11-30 1981-03-24 Merck & Co., Inc. Inhibitor of dihydrofolate reductase
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use

Also Published As

Publication number Publication date
FI813546L (fi) 1982-05-12
SU1318148A3 (ru) 1987-06-15
GB2087881B (en) 1985-05-15
ES8405379A1 (es) 1984-06-01
IL64256A (en) 1988-01-31
US4587342A (en) 1986-05-06
YU46697B (sh) 1994-04-05
NZ198932A (en) 1985-05-31
ES521201A0 (es) 1984-06-01
NO160137B (no) 1988-12-05
YU198183A (en) 1984-04-30
YU198383A (en) 1984-04-30
US4438267A (en) 1984-03-20
PL239279A1 (en) 1983-08-01
EP0051879A2 (en) 1982-05-19
CS273153B2 (en) 1991-03-12
YU198283A (en) 1984-04-30
PL233754A1 (en) 1983-08-01
PL139523B1 (en) 1987-01-31
PH25053A (en) 1991-01-28
FI76333C (fi) 1988-10-10
HU188762B (en) 1986-05-28
ES8405377A1 (es) 1984-06-01
AR245447A1 (es) 1994-01-31
JPS57114581A (en) 1982-07-16
YU266381A (en) 1984-04-30
PH22654A (en) 1988-10-28
ES506969A0 (es) 1983-07-01
GR81317B (no) 1984-12-11
SU1306473A3 (ru) 1987-04-23
PL239280A1 (en) 1983-08-01
KR830007628A (ko) 1983-11-04
PL139827B1 (en) 1987-02-28
IT8149676A0 (it) 1981-11-10
ES8307759A1 (es) 1983-07-01
ZM9481A1 (en) 1983-11-21
IL64256A0 (en) 1982-02-28
AU549449B2 (en) 1986-01-30
JPH0474351B2 (no) 1992-11-26
PL239278A1 (en) 1983-08-01
SG62686G (en) 1987-03-27
PL139427B1 (en) 1987-01-31
AU7733481A (en) 1982-05-20
CA1186310A (en) 1985-04-30
MC1418A1 (fr) 1982-10-18
ES521203A0 (es) 1984-06-01
PL139828B1 (en) 1987-02-28
EP0051879B1 (en) 1986-02-05
YU43551B (en) 1989-08-31
NO813804L (no) 1982-05-12
US4603136A (en) 1986-07-29
DE3173752D1 (en) 1986-03-20
IE52128B1 (en) 1987-06-24
DK172884B1 (da) 1999-09-06
ES8405380A1 (es) 1984-06-01
IT1210589B (it) 1989-09-14
PT73960B (en) 1983-11-23
KR880001736B1 (ko) 1988-09-10
ES521204A0 (es) 1984-06-01
IE812631L (en) 1982-05-11
RU1819264C (ru) 1993-05-30
YU144288A (en) 1990-04-30
CY1419A (en) 1988-04-22
FI76333B (fi) 1988-06-30
US4761475A (en) 1988-08-02
CS825781A2 (en) 1990-07-12
PT73960A (en) 1981-12-01
DK496681A (da) 1982-05-12
DD201896A5 (de) 1983-08-17
SU1535379A3 (ru) 1990-01-07
ZA817780B (en) 1983-06-29
GB2087881A (en) 1982-06-03
ES8405378A1 (es) 1984-06-01
YU42444B (en) 1988-08-31
EG16107A (en) 1987-10-30
EP0051879A3 (en) 1982-08-04
SU1424732A3 (ru) 1988-09-15
HK23388A (en) 1988-04-08
NO1994029I1 (no) 1994-12-29
MY8600678A (en) 1986-12-31
ES521202A0 (es) 1984-06-01

Similar Documents

Publication Publication Date Title
NO160137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,4-diamino-5-(substituerte)-pyrimidiner.
NO156785B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
NO158419C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2-diaminocyklobuten-3,4-dioner.
NO164025C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
NO160850C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-(bicykliske heterocyklyl)-4-piperidinaminer.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO161497C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9a-aza-9a-homoerytromycin-derivater.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NO164541C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater.
NO158460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO871044L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater.
NO155665C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,7,7a-tetrahydro-4h-thieno-(3,2-c)-pyridin-2-on-derivater.
NO152649C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fenylalkylaminer.
NO160370C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive penam-1,1-dioksyd-forbindelser.
NO153137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte pyrido(1,2-a)pyrimidiner.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
NO873680L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfonamido-etyl-forbindelser.
NO158800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenderivater.
NO156167C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinon-derivater.
NO163570C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acylaminomitosaner.
NO162188C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinoliner.
NO881768L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
NO152843C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidopyrimidiner.
NO162191C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 6-fenetyl-amino-alkyl-7-hydroksy-furo-(3,4-c)-pyridin-derivater.

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN NOVEMBER 2001